Alpha Tau to Speak at Jefferies Healthcare Conference

JERUSALEM, May 21, 2024 – Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company"), a pioneer in alpha-radiation cancer therapy, revealed that its Chief Financial Officer, Raphi Levy, will deliver a corporate overview and update at the Jefferies Global Healthcare Conference scheduled for June 5th, 2024. The event will take place in New York, NY, from 1:30 PM to 1:55 PM EST. During the conference, Mr. Levy will also be available for individual meetings with investors.

Alpha Tau Medical Ltd., an Israeli company established in 2016, specializes in the research, development, and potential commercialization of its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. The company's focus is on treating solid tumors using this innovative approach. The Alpha DaRT technology originated from research by Prof. Itzhak Kelson and Prof. Yona Keisari of Tel Aviv University.

Alpha DaRT is engineered to deliver potent and targeted alpha-irradiation directly into solid tumors. The method involves the intratumoral administration of radium-224 impregnated sources. As the radium decays, its short-lived daughter isotopes are released, dispersing high-energy alpha particles which aim to obliterate the tumor. Due to the limited diffusion range of these alpha-emitting atoms, the therapy is designed to minimize damage to surrounding healthy tissues, focusing its destructive power on the tumor itself.

Alpha Tau Medical Ltd. continues to advance its promising cancer therapy, with significant potential to revolutionize the treatment of solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!